Table 2 Patient classification and time to treatment outcomes
From: Favorable outcomes with reduced steroid use in juvenile dermatomyositis
| Monocyclic, n = 10 | Chronic Continuous, n = 18 | ||
|---|---|---|---|
| Myositis control (months) |
6.6 (4.3–7.8) (n = 10) |
6 (3.7–17.6) (n = 17) | p = 0.334 |
| Cutaneous disease control (months) |
15.7 (13.1–17) (n = 9) |
29.6, (16.4–63.3) (n = 12) | p = 0.018 |
| Duration of steroid use (months) |
8 (4.5–8.8) (n = 9) |
9.9 (7–30.4) (n = 18) | p = 0.145 |